Mar 05, 2021 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 01, 2021 4:05 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
Feb 18, 2021 4:01 pm EST Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
Feb 08, 2021 9:00 am EST Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Jan 19, 2021 4:14 pm EST Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
Jan 10, 2021 4:06 pm EST Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference
Jan 06, 2021 8:30 am EST Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Jan 04, 2021 7:30 am EST Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease